The Experts below are selected from a list of 255 Experts worldwide ranked by ideXlab platform
Matthias Augustin - One of the best experts on this subject based on the ideXlab platform.
-
Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review.
Dermatologic Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis.
-
Keratolytics and Emollients and Their Role in the Therapy of Psoriasis: a Systematic Review
Dermatology and Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction: Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis. Methods: A systematic literature search was conducted in Medline via PubMed regarding reviews, meta-analyses, and trials published from January 1983 to December 2013 dealing with topical administration of emollients and Keratolytics in patients with psoriasis. A subsequent search in EMBASE regarding clinical trials published from 1983 to 2013 was performed to complement the findings. Results: A total of 60 publications met the inclusion criteria for full-text evaluation. While current reviews, meta-analyses, and guidelines state that adjuvant therapy with emollients and Keratolytics should be an obligatory part in the therapy of psoriasis to facilitate descaling and/or penetration enhancement, comprehensive trials on these agents are missing, with the exception of combination products containing salicylic acid and corticosteroids. In the mentioned trials, addition of salicylic acid was beneficial in inducing a more rapid onset of action as well as a reduction of severity parameters and the area affected. However, its use has substantial limitations in young children, in patients with renal/hepatic impairment, with widespread psoriasis, those undergoing phototherapy, or those concomitantly treated with calcipotriene/systemic salicylates. Conclusion: In view of these shortcomings, there is a need for well-designed studies on suitable Keratolytic alternatives to salicylic acid offering an indisputable positive benefit–risk ratio.
Howard I Maibach - One of the best experts on this subject based on the ideXlab platform.
-
bioequivalence in Keratolytic activity of formulations vs its vehicle and comparator formulation randomized double blind clinical trial
Skinmed, 2013Co-Authors: Hongbo Zhai, Yue Zheng, Peter Matravers, Deborah Hicks, Sheree Wiener, Howard I MaibachAbstract:: This study assessed the bioequivalence, using Keratolytic efficacy, of topical preparations studied in humans using adhesive tape stripping and biophysical methods. Ten healthy patients (3 men and 7 women [7 Caucasians and 3 Asians] mean age, 47 years) completed the study. Each coded product was randomly applied to the back according to the designated time of each sample. In addition, an untreated site (normal skin), and an untreated occluded site (chamber only) served as controls. At the end of the application time, each site was rinsed with tap water and then covered with a plastic chamber for 6 hours. Following removal of the chamber, the site was stripped for protein assay and squamometry analysis. This extends previous observations discerning bioequivalence resulting from different active materials with varying mechanism of action and potency on the skin. Results showed no significant difference between tested products. The novel formulations were of equal Keratolytic activity to the "standard" (comparator) and hence bioequivalent in Keratolytic activity.
-
Keratolytic properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man
Skin Pharmacology and Physiology, 2006Co-Authors: J M Waller, Frank Dreher, S Behnam, C Ford, T Tiet, Gerald D Weinstein, Howard I MaibachAbstract:Objectives: Retinoic acid (RA) and benzoyl peroxide (BP) were studied, comparing their Keratolytic efficacy and water barrier disruption to that of salicylic acid (SA), a well-estab
-
cutaneous bioassay of salicylic acid as a Keratolytic
International Journal of Pharmaceutics, 2005Co-Authors: Saqib J Bashir, Hongbo Zhai, Frank Dreher, Ailean Chew, Cheryl Levin, Robert A Stern, Howard I MaibachAbstract:Keratolytic efficacy of topical preparations containing salicylic acid was studied in humans utilizing adhesive tape stripping and quantifying SC removal by protein analysis. In combination with tape stripping, squamometry was used to evaluate the influence of salicylic acid on skin surface scaliness and desquamation. Furthermore, skin barrier perturbation and skin irritancy was recorded and related to the dermatopharmacological effect of the preparations. In contrast to squamometry, tape stripping combined with protein analysis was sensitive in detecting Keratolytic effect of salicylic acid within hours of application. Importantly, whereas the pH of the preparations only minimally influenced efficacy, local dermatotoxicity was significantly increased at acidic pH. This indicates that the quest to increase the amount of free, non-dissociated SA is, in fact, counterproductive as the more acidic preparations resulted in skin irritation and barrier disruption.
Leon Kircik - One of the best experts on this subject based on the ideXlab platform.
-
Salicylic Acid 6% in an Ammonium Lactate Emollient Foam Vehicle in the Treatment of Mild-to-Moderate Scalp Psoriasis
J Drugs Dermatol, 2011Co-Authors: Leon KircikAbstract:Scalp psoriasis is a common life-al tering skin condition causing a great deal of distress. It significantly affects quality of life and is difficult to manage. Treatment can provide variable results, often impacting patient compliance with therapy. Salicylic acid is used as adjunctive therapy to other topical treatments because of its marked Keratolytic effect. Its effectiveness as a monotherapy is not fully understood. An emollient foam formulation of 6% salicylic acid (Salkera) in an ammonium lactate vehicle has recently become available. Efficacy, tolerability and patient acceptability of salicylic acid 6% emollient foam were assessed in an open-label pilot study of 10 subjects with scalp psoriasis. All psoriasis severity parameters were reduced with a significant decrease in Psoriasis Scalp Severity Index (PSSI) score from 15.3 to 3.0 after four weeks of monotherapy (P
Arnd Jacobi - One of the best experts on this subject based on the ideXlab platform.
-
Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review.
Dermatologic Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis.
-
Keratolytics and Emollients and Their Role in the Therapy of Psoriasis: a Systematic Review
Dermatology and Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction: Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis. Methods: A systematic literature search was conducted in Medline via PubMed regarding reviews, meta-analyses, and trials published from January 1983 to December 2013 dealing with topical administration of emollients and Keratolytics in patients with psoriasis. A subsequent search in EMBASE regarding clinical trials published from 1983 to 2013 was performed to complement the findings. Results: A total of 60 publications met the inclusion criteria for full-text evaluation. While current reviews, meta-analyses, and guidelines state that adjuvant therapy with emollients and Keratolytics should be an obligatory part in the therapy of psoriasis to facilitate descaling and/or penetration enhancement, comprehensive trials on these agents are missing, with the exception of combination products containing salicylic acid and corticosteroids. In the mentioned trials, addition of salicylic acid was beneficial in inducing a more rapid onset of action as well as a reduction of severity parameters and the area affected. However, its use has substantial limitations in young children, in patients with renal/hepatic impairment, with widespread psoriasis, those undergoing phototherapy, or those concomitantly treated with calcipotriene/systemic salicylates. Conclusion: In view of these shortcomings, there is a need for well-designed studies on suitable Keratolytic alternatives to salicylic acid offering an indisputable positive benefit–risk ratio.
Anke Mayer - One of the best experts on this subject based on the ideXlab platform.
-
Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review.
Dermatologic Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis.
-
Keratolytics and Emollients and Their Role in the Therapy of Psoriasis: a Systematic Review
Dermatology and Therapy, 2015Co-Authors: Arnd Jacobi, Anke Mayer, Matthias AugustinAbstract:Introduction: Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and Keratolytics in the treatment of psoriasis. Methods: A systematic literature search was conducted in Medline via PubMed regarding reviews, meta-analyses, and trials published from January 1983 to December 2013 dealing with topical administration of emollients and Keratolytics in patients with psoriasis. A subsequent search in EMBASE regarding clinical trials published from 1983 to 2013 was performed to complement the findings. Results: A total of 60 publications met the inclusion criteria for full-text evaluation. While current reviews, meta-analyses, and guidelines state that adjuvant therapy with emollients and Keratolytics should be an obligatory part in the therapy of psoriasis to facilitate descaling and/or penetration enhancement, comprehensive trials on these agents are missing, with the exception of combination products containing salicylic acid and corticosteroids. In the mentioned trials, addition of salicylic acid was beneficial in inducing a more rapid onset of action as well as a reduction of severity parameters and the area affected. However, its use has substantial limitations in young children, in patients with renal/hepatic impairment, with widespread psoriasis, those undergoing phototherapy, or those concomitantly treated with calcipotriene/systemic salicylates. Conclusion: In view of these shortcomings, there is a need for well-designed studies on suitable Keratolytic alternatives to salicylic acid offering an indisputable positive benefit–risk ratio.
